These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 19421227

  • 1. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.
    Ikezoe T, Yang J, Nishioka C, Takezaki Y, Tasaka T, Togitani K, Koeffler HP, Yokoyama A.
    Leukemia; 2009 Sep; 23(9):1564-76. PubMed ID: 19421227
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
    Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, Hassler DF, Smith GK, Gontarek RR, Courtney MP, Sutton D, Diamond MA, Jackson JR, Laquerre SG.
    Cancer Res; 2009 Sep 01; 69(17):6969-77. PubMed ID: 19690138
    [Abstract] [Full Text] [Related]

  • 5. Polo-like kinase 1 (Plk1) is expressed by cutaneous T-cell lymphomas (CTCLs), and its downregulation promotes cell cycle arrest and apoptosis.
    Nihal M, Stutz N, Schmit T, Ahmad N, Wood GS.
    Cell Cycle; 2011 Apr 15; 10(8):1303-11. PubMed ID: 21436619
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Polo-like kinase 1 regulates activation of AMP-activated protein kinase (AMPK) at the mitotic apparatus.
    Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Menendez JA.
    Cell Cycle; 2011 Apr 15; 10(8):1295-302. PubMed ID: 21474997
    [Abstract] [Full Text] [Related]

  • 8. Inhibitory effect of Polo-like kinase 1 depletion on mitosis and apoptosis of gastric cancer cells.
    Chen XH, Lan B, Qu Y, Zhang XQ, Cai Q, Liu BY, Zhu ZG.
    World J Gastroenterol; 2006 Jan 07; 12(1):29-35. PubMed ID: 16440413
    [Abstract] [Full Text] [Related]

  • 9. Polo-like kinase 1 inhibitors in mono- and combination therapies: a new strategy for treating malignancies.
    Christoph DC, Schuler M.
    Expert Rev Anticancer Ther; 2011 Jul 07; 11(7):1115-30. PubMed ID: 21806334
    [Abstract] [Full Text] [Related]

  • 10. Differential Cellular Effects of Plk1 Inhibitors Targeting the ATP-binding Domain or Polo-box Domain.
    Shin SB, Woo SU, Yim H.
    J Cell Physiol; 2015 Dec 07; 230(12):3057-67. PubMed ID: 25975351
    [Abstract] [Full Text] [Related]

  • 11. The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma.
    Stewart HJ, Kishikova L, Powell FL, Wheatley SP, Chevassut TJ.
    Exp Hematol; 2011 Mar 07; 39(3):330-8. PubMed ID: 21184800
    [Abstract] [Full Text] [Related]

  • 12. An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies.
    Spaniol K, Boos J, Lanvers-Kaminsky C.
    Anticancer Drugs; 2011 Jul 07; 22(6):531-42. PubMed ID: 21637161
    [Abstract] [Full Text] [Related]

  • 13. Clinicopathological significance of Polo-like kinase 1 (PLK1) expression in human malignant glioma.
    Cheng MW, Wang BC, Weng ZQ, Zhu XW.
    Acta Histochem; 2012 Sep 07; 114(5):503-9. PubMed ID: 22000864
    [Abstract] [Full Text] [Related]

  • 14. A specific inhibitor of polo-like kinase 1, GSK461364A, suppresses proliferation of Raji Burkitt's lymphoma cells through mediating cell cycle arrest, DNA damage, and apoptosis.
    Ergul M, Bakar-Ates F.
    Chem Biol Interact; 2020 Dec 01; 332():109288. PubMed ID: 33075310
    [Abstract] [Full Text] [Related]

  • 15. Inhibition of polo-like kinase 1 promotes hyperthermia sensitivity via inactivation of heat shock transcription factor 1 in human retinoblastoma cells.
    Yunoki T, Tabuchi Y, Hayashi A, Kondo T.
    Invest Ophthalmol Vis Sci; 2013 Dec 23; 54(13):8353-63. PubMed ID: 24366665
    [Abstract] [Full Text] [Related]

  • 16. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
    Xu WJ, Zhang S, Yang Y, Zhang N, Wang W, Liu SY, Tian HW, Dai L, Xie Q, Zhao X, Wei YQ, Deng HX.
    Cancer Biother Radiopharm; 2011 Aug 23; 26(4):427-36. PubMed ID: 21797676
    [Abstract] [Full Text] [Related]

  • 17. Therapeutic polo-like kinase 1 inhibition results in mitotic arrest and subsequent cell death of blasts in the bone marrow of AML patients and has similar effects in non-neoplastic cell lines.
    Münch C, Dragoi D, Frey AV, Thurig K, Lübbert M, Wäsch R, Bogatyreva L, Hauschke D, Lassmann S, Werner M, May AM.
    Leuk Res; 2015 Apr 23; 39(4):462-70. PubMed ID: 25697066
    [Abstract] [Full Text] [Related]

  • 18. Overexpression of human ABCB1 in cancer cells leads to reduced activity of GSK461364, a specific inhibitor of polo-like kinase 1.
    Wu CP, Hsiao SH, Luo SY, Tuo WC, Su CY, Li YQ, Huang YH, Hsieh CH.
    Mol Pharm; 2014 Oct 06; 11(10):3727-36. PubMed ID: 25192198
    [Abstract] [Full Text] [Related]

  • 19. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.
    Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D, Cappella P, Caruso M, Casolaro A, Ciavolella A, Cucchi U, De Ponti A, Felder E, Fiorentini F, Galvani A, Gianellini LM, Giorgini ML, Isacchi A, Lansen J, Pesenti E, Rizzi S, Rocchetti M, Sola F, Moll J.
    Mol Cancer Ther; 2012 Apr 06; 11(4):1006-16. PubMed ID: 22319201
    [Abstract] [Full Text] [Related]

  • 20. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.
    Lansing TJ, McConnell RT, Duckett DR, Spehar GM, Knick VB, Hassler DF, Noro N, Furuta M, Emmitte KA, Gilmer TM, Mook RA, Cheung M.
    Mol Cancer Ther; 2007 Feb 06; 6(2):450-9. PubMed ID: 17267659
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.